Syntheses and antimicrobial activities of ogipeptin derivatives. 2021

Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan. Electronic address: takiguchi.shingo.nj@rdn.daiichisankyo.co.jp.

Novel cyclic peptide derivatives based on ogipeptins A, B, C, and D were synthesized. Starting with a mixture of ogipeptins A-D, a practical four-step synthetic procedure was followed to prepare novel derivatives with various kinds of acyl side chains. Among the 45 new synthetic derivatives identified, the antibacterial activities of compounds 8-3 and 8-38 were comparable with those of ogipeptin A. In in vitro nephrotoxicity screening using LLC-PK1 cells, compounds 8-3 and 8-38 showed significantly lower cytotoxicity (LD20 > 480 μM) than colistin (LD20 = 44.2 μM).

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
October 1984, Chemical & pharmaceutical bulletin,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
December 1986, The Journal of antibiotics,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
November 1973, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
November 1974, Journal of pharmaceutical sciences,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
August 1984, Archiv der Pharmazie,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
September 1982, Chemical & pharmaceutical bulletin,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
May 1992, The Journal of antibiotics,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
March 2015, Chemistry (Weinheim an der Bergstrasse, Germany),
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
January 1992, Chemical & pharmaceutical bulletin,
Shingo Takiguchi, and Hidehito Homma, and Tetsunori Fujisawa, and Yuki Hirota-Takahata, and Yasunori Ono, and Masaaki Kizuka, and Yuki Ishii, and Satomichi Yoshimura, and Takahide Nishi
March 2008, Journal of agricultural and food chemistry,
Copied contents to your clipboard!